Durgical
EN
Open the app

Myeloma care: bones, kidneys, infections and treatment principles

  • Treatment and support

People with myeloma now live for many years. Getting there means treating the clone and, just as much, protecting the bones, kidneys and immune system.

Updated

What it is

Myeloma treatment has two tracks run together. The first controls the plasma cell clone with combinations of drug classes: proteasome inhibitors, immunomodulatory drugs, anti-CD38 antibodies and steroids, followed in fit patients by high-dose melphalan with autologous stem cell rescue and then maintenance. The second prevents and treats the damage the clone causes: bone lesions and fractures, high calcium, kidney injury, anaemia, infections and the toxicities of treatment. Myeloma is rarely cured, but long remissions are common.

What to know

  • Typical induction is a three- or four-drug combination, for example an anti-CD38 antibody, a proteasome inhibitor, an immunomodulatory drug and dexamethasone.
  • Fit patients usually go on to high-dose melphalan with autologous stem cell transplant, then lenalidomide maintenance; others continue a non-transplant combination.
  • Relapse is expected: later lines use other drug classes, BCMA-directed CAR-T cells and bispecific antibodies.
  • Bone protection: a bisphosphonate (such as zoledronic acid) or denosumab for patients on treatment, plus radiotherapy or vertebral augmentation for painful or unstable lesions.
  • Kidney protection: fluids, treating high calcium, stopping NSAIDs and avoiding contrast where possible, and starting anti-myeloma treatment quickly to cut light-chain production.
  • Infection protection: inactivated vaccines, antiviral prophylaxis against shingles with proteasome inhibitors and anti-CD38 antibodies, and immunoglobulin replacement for recurrent infections with low antibodies.

How it is done (and why)

  1. Confirm active myeloma (organ damage or a myeloma-defining marker) and assess genetic risk on the marrow.
  2. Deal with emergencies first: high calcium, kidney injury, cord compression, hyperviscosity and infection.
  3. Decide on transplant eligibility by fitness, not by age alone.
  4. Start induction combining drug classes, plus bone protection and infection prophylaxis.
  5. Fit patients: collect stem cells, give high-dose melphalan with autologous rescue, then maintenance.
  6. Monitor response by paraprotein, free light chains and, increasingly, MRD on the marrow.
  7. At relapse, switch to drug classes the clone has not yet resisted; consider CAR-T or bispecific antibodies.

The drug classes and their typical problems

ClassExamplesHow it worksWatch for
Proteasome inhibitorBortezomibBlocks protein disposal, so plasma cells choke on their own antibodyPeripheral neuropathy, shingles reactivation
Immunomodulatory drugLenalidomide, thalidomideChanges the clone's protein degradation and boosts immune attackVenous thrombosis, birth defects, low counts
Anti-CD38 antibodyDaratumumabMarks plasma cells for immune destructionInfusion reactions, interference with blood bank testing
SteroidDexamethasoneKills plasma cells directlyHigh glucose, mood change, infection
Bone-protecting drugZoledronic acid, denosumabSwitch off osteoclastsOsteonecrosis of the jaw, low calcium, kidney effects (bisphosphonate)

Risks and precautions

  • Daratumumab binds CD38 on red cells and makes every antibody screen look positive; the blood bank must be told, and the patient's red cell type is extended before the first dose.
  • Immunomodulatory drugs with steroids raise the risk of venous thrombosis, so every patient receives thromboprophylaxis matched to their risk.
  • A dental check before starting a bisphosphonate or denosumab, and avoiding extractions during treatment, lowers the risk of jaw osteonecrosis.
  • New back pain with leg weakness or numbness, or bladder change, is cord compression until an urgent MRI shows otherwise.
  • Lenalidomide and thalidomide cause birth defects, so a strict pregnancy prevention programme applies.

Monitoring and next step

  • Response: serum and urine paraprotein, serum free light chains, and MRD on the marrow when available.
  • Each visit: full count, calcium, creatinine and albumin; immunoglobulin levels when infections recur.
  • Before daratumumab: group, antibody screen and extended red cell phenotype or genotype.
  • Before bone-protecting drugs: dental review, calcium and vitamin D, creatinine.
  • Back pain with neurological signs: whole-spine MRI the same day.

Common traps

  • Giving NSAIDs for bone pain: they worsen kidney injury in myeloma.
  • Ignoring a 'panreactive' antibody screen after daratumumab: the drug causes it, so warn the blood bank before treatment starts.
  • Forgetting thromboprophylaxis with lenalidomide or thalidomide: both drugs need it.
  • Starting a bisphosphonate without a dental assessment: it raises the risk of jaw osteonecrosis.
  • Judging transplant eligibility by age alone: fitness, not age, decides it.

Test yourself

Think of the answer, then tap the question to see it.

Why does daratumumab cause problems in the blood bank?

It binds CD38 on donor and patient red cells, so the antibody screen and crossmatch react with everything and can mask a real antibody; the red cell type is extended before treatment.

Why are NSAIDs avoided for bone pain in myeloma?

They reduce kidney blood flow in kidneys already strained by light chains, high calcium and dehydration, and can precipitate acute kidney injury.

What is checked before starting a bisphosphonate or denosumab, and why?

A dental assessment, because these drugs can cause osteonecrosis of the jaw, especially after extractions.

A patient starts lenalidomide with dexamethasone. Which additional preventive measure is needed?

Thromboprophylaxis, because the combination raises the risk of venous thrombosis, plus a pregnancy prevention programme where relevant.

Add to my cards (4)

Elsewhere in DurgiPedia

Connections

← All of haematology

Educational content; it does not replace assessment by a doctor or your institution's protocols. It contains no doses.

Sources: Multiple Myeloma (StatPearls (NCBI Bookshelf), 2023); Plasma Cell Neoplasms (Including Multiple Myeloma) Treatment (PDQ®)–Health Professional Version (National Cancer Institute, 2025); Multiple myeloma: MedlinePlus Medical Encyclopedia (MedlinePlus, US National Library of Medicine, 2026).

Spotted a mistake?We are always improving for the community. Tell us what is wrong and our team will review it.Report a mistake

Representative model, for educational purposes only.